Workflow
Capricor Therapeutics(CAPR) - 2023 Q4 - Annual Results

● Plan to have a Type-B meeting with FDA in the first quarter of 2024 to discuss commercial manufacturing planning with an aim to expedite the BLA pathway. ● Plan to report 3-year HOPE-2 OLE data in the second quarter of 2024. ● Plan to complete HOPE-3 (Cohort B) enrollment in the second quarter of 2024. ● Plan to report topline data from HOPE-3 (Cohort A) in the fourth quarter of 2024. ● Continue to explore opportunities for additional partnerships outside of the U.S. and Japan to support the potential com ...